Blue Distinction by Blue Cross
Fox Chase Cancer Center has been designated as one of the Blue Distinction CentersSM for Complex and Rare Cancers by Blue Cross Blue Shield Association and Independence Blue Cross.
The Fox Chase-Temple University Hospital Bone Marrow Transplant Program has also been designated a Blue Distinction Center for Transplants.
Blue Distinction is a nationwide program created by Blue Cross Blue Shield Association to give consumers the information they need to make smart health care decisions and to work with their health care providers on improving the quality and affordability of their medical care. Blue Distinction identifies specialty centers that offer the best practices and highest standards in cardiac care, bariatric surgery, transplants and complex and rare cancers.
Fox Chase has earned
Blue Distinction CenterSM for Complex and Rare Cancers designation
for treatment of
head and neck cancer,
soft tissue sarcoma.
With complex and rare cancers comprising approximately 15 percent of new cancer cases each year, it is difficult for patients to locate and/or research facilities that specialize in this area — the Blue Distinction designation helps patients identify institutions with expertise in this specialty.
Fox Chase has earned the Blue Distinctions Center for Complex and Rare Cancers designation for esophageal cancer, pancreatic cancer, gastric cancer, rectal cancer, bladder cancer, head and neck cancer, thyroid cancer and soft tissue sarcoma.
The complex and rare cancers designation is awarded to institutions that offer multidisciplinary treatment planning and complex, major surgical treatments with subspecialty training and distinguished clinical expertise in complex and rare cancer such as esophageal cancer, bladder cancer, liver cancer, thyroid cancer, and 10 other complex and rare subtypes of cancer.
Blue Distinction Center for Transplants
Since its start in 1990, the Fox Chase-Temple BMT Program has performed more than 1,500 transplants for patients with leukemia, lymphoma, multiple myeloma, aplastic anemia and other disorders. The Program is fully accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), and participates in the National Marrow Donor Program (NMDP).